Pfizer AG

Danish Court Issues Preliminary Injunction That Prohibits Sale of Generic Lipitor Product

    New York (ots/PRNewswire) -

    Pfizer Inc said today that a Danish court has granted a preliminary injunction against Nomeco A/S -- the largest pharmaceutical wholesaler in Denmark -- that prohibits the sale of a generic version of Lipitor by generics manufacturer Ranbaxy. The injunction, issued by the Bailiff's Court of the Copenhagen City Court in Denmark and subject to possible appeal by Nomeco, requires Ranbaxy's generic atorvastatin product to be withdrawn from the Danish market pending the outcome of a patent infringement trial that has not yet been scheduled.

    At issue are three Pfizer patents covering atorvastatin calcium, the active ingredient in Lipitor, as well as processes and intermediate compounds used to make atorvastatin. The latest-expiring of the patents provides coverage for Lipitor through November, 2011. The Bailiff's Court ruled in Pfizer's favor on all three patents.

    "This ruling is another significant milestone in our defense of Lipitor patents around the world," said Pfizer Senior Vice President and General Counsel Allen Waxman. "And it's an important outcome for Pfizer and other medical innovators who invest in high-risk research to develop life-saving medicines for millions of patients," added Karin Verland, country manager of Pfizer Denmark.

ots Originaltext: Pfizer Inc.
Im Internet recherchierbar: http://www.presseportal.ch

Contact:
Bryant Haskins, +1-212-733-8719 / Company News On-Call:  Pfizer's
press releases are available through PR Newswire's Company News
On-Call service on PRN's Web Site.  Visit
http://www.prnewswire.com/comp/688250.html  Photo:  A free corporate
logo to accompany this story is available immediately via Wieck Photo
Database to any media with telephoto receiver
or electronic darkroom, PC or Macintosh, that can accept overhead
transmissions.  To retrieve a logo, please call +1-972-392-0888 /
Company News On-Call:  http://www.prnewswire.com/comp/688250.html



Weitere Meldungen: Pfizer AG

Das könnte Sie auch interessieren: